Clinical trials: Hematopoietic
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Telehealth Intervention for Improving Distress and Financial Toxicity in the Caregivers
This clinical trial assesses whether resource identification for primary caregivers can affect financial stress, quality of life, depression, and the general belief in the ability to cope with daily life.
- Trial name
- NCT06709404
- Testing
- Telemedicine, Survey administration, Electronic health record review
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Myelodysplastic Syndromes
Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00398047
- Testing
- Azacitadine and Hematopoietic Growth Factors
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Wake Forest University Health Sciences
Leukemia, Myelodysplastic Syndrome
Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation
This study will test the safety of giving you specialized white cells from your donor. They are called WT1 sensitized T cells. They have been grown in the lab and are immunized against a protein.
- Trial name
- NCT00620633
- Testing
- WT1-sensitized T cells
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sickle Cell Anemia, Beta-thalassemia Major
T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
The purpose of this study is to evaluate what effect, if any, mismatched unrelated volunteer donor and/or haploidentical related donor stem cell transplant may have on severe sickle cell disease and other transfusion dependent…
- Conditions
- Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia
- Trial name
- NCT03653338
- Testing
- CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Paul Szabolcs
Hematopoietic Stem Cell Transplantation, Malnutrition
Body Composition Changes During Stem Cell Transplantation: The Case Of Lymphoma Patients
Skeletal Muscle Index (SMI) and Visceral Adipose Ratio (VAR) assess body composition changes and disclose malnutrition risk effectively.
- Conditions
- Hematopoietic Stem Cell Transplantation, Malnutrition, Metabolic Syndrome
- Trial name
- NCT02983643
- Where
- Lebanon
- Volunteers
- 105 people
- Sponsor
- American University of Beirut Medical Center
Graft-versus-host-disease, Graft Versus Host Disease, Chronic
Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD
Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) represents the only curative option for many patients diagnosed with various hematologic neoplasms.
- Conditions
- Graft-versus-host-disease, Graft Versus Host Disease, Chronic, Stem Cell Transplant Complications, Hematological Malignancy
- Trial name
- NCT06279585
- Testing
- Physical therapy
- Where
- Spain
- Volunteers
- 108 people
- Sponsor
- University of Seville
Multiple Myeloma, Auto Stem Cell Transplant
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant…
- Trial name
- (Mel/MelVel) (NCT01241708)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Hackensack Meridian Health
Hematologic Malignancies, Nonmalignant Diseases
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609814
- Testing
- Clofarabine, Fludarabine Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Acute Lymphoblastic Leukemia, Adult
Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia
The main purpose of the project is to evaluate the disease free survival and overall survival in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT)…
- Trial name
- NCT03339700
- Testing
- Gemcitabine, Busulfan, Cyclophosphamide
- Where
- Mexico
- Volunteers
- 15 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Multiple Sclerosis
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares.
- Trial name
- NCT00273364
- Testing
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Northwestern University
Kidney Cancer
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Metastatic Kidney Cancer That Cannot Be Removed By Surgery
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00243009
- Testing
- cyclosporine, fludarabine phosphate, mycophenolate mofetil
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- OHSU Knight Cancer Institute
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT.
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT01402687
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Dana-Farber Cancer Institute
HSCT, Ph+ ALL
Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL
To study the minimal residual disease (MRD) clearance rate of olverembatinib combined with inotuzumab ozogamicin as first-line consolidation chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic…
- Trial name
- NCT07443488
- Testing
- Olverembatinib+INO
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
Background: Bronchiolitis obliterans syndrome (BOS) is a complication people can experience after hematopoietic stem cell transplant. It usually affects people with chronic graft versus host disease (cGVHD).
- Conditions
- Chronic Graft vs Host Disease, Chronic Graft-Versus-Host Disease, Bronchiolitis Obliterans Syndrome
- Trial name
- NCT02669251
- Testing
- MPH966
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Vitamin D Deficiency
High Dose Vitamin D Replacement in Patients Undergoing Hematopoietic Stem Cell Transplantation
The purpose of this study is to test the efficacy and safety of high dose vitamin D therapy among HSCT patients in a tiered, step-wise manner (step one/two) in order to define treatment doses capable of providing vitamin D…
- Trial name
- NCT02876822
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Placental Transfusion, Stem Cells
Placental Transfusion Methods and Stem Cells
To measure the levels of endothelial progenitor cells and CD34+ hematopoietic stem cells levels, and placental residual volume by delayed cord clamping, umbilical cord milking or immediate cord clamping in newborns at different…
- Trial name
- NCT03983902
- Testing
- Delayed cord clamping, Umbilical cord milking, Immediate cord clamping
- Volunteers
- 96 people
- Sponsor
- Ankara University
Hematopoietic Stem Cell Transplantation
Ambulatory Physical Exercise Program in Hematopoietic Stem Cell Transplantation Recipients
The proposed study in an inception cohort of patients with hematological malignancies treated with PBSCT is designed to evaluate the effects of a physical exercise intervention on muscular-skeletal, physical activity and quality…
- Trial name
- NCT00402753
- Testing
- Ambulatory Physical Exercise Program
- Where
- 4 sites in Netherlands, Switzerland
- Volunteers
- 128 people
- Sponsor
- University of Zurich
Acute Lymphoblastic Leukemia, Myeloblastic Leukemia
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and calcineurin inhibitor in children and young adults with hematoloblastosis after myeloablative…
- Conditions
- Acute Lymphoblastic Leukemia, Myeloblastic Leukemia, Biphenotypic Acute Leukemia, Malignant Lymphoma
- Trial name
- NCT05515029
- Testing
- GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor
- Where
- Russia
- Volunteers
- 56 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
MDS
Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk
Comparison of survival in patients with or without a matched donor at 36 months
- Trial name
- NCT02757989
- Testing
- transplantation
- Where
- 37 sites in France
- Volunteers
- 79 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Beta-Thalassemia
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
The main goal of this study is to find out if the blood disorder called transfusion-dependent beta thalassemia can be safely treated by modifying blood stem cells.
- Trial name
- NCT06364774
- Testing
- ALS20
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Philadelphia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.